Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M8,093Revenue $M934Net Margin (%)-5.6Z-Score1.4
Enterprise Value $M10,496EPS $2.2Operating Margin %1.9F-Score5
P/E(ttm))0Cash Flow Per Share $3.6Pre-tax Margin (%)-8.6Higher ROA y-yN
Price/Book15.410-y EBITDA Growth Rate %0Quick Ratio0.8Cash flow > EarningsY
Price/Sales6.25-y EBITDA Growth Rate %0Current Ratio0.9Lower Leverage y-yY
Price/Cash Flow11.8y-y EBITDA Growth Rate %-30.0ROA % (ttm)-2.0Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-11.3Less Shares Outstanding y-yY
Payout Ratio %0Shares Outstanding M63.7ROI % (ttm)2.6Gross Margin Increase y-yN

Gurus Latest Trades with SLXP

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
SLXPAndreas Halvorsen 2014-06-30 Add0.74%$97.7 - $125.07
($110.33)
$ 125.9214%Add 86.19%2,889,303
SLXPJoel Greenblatt 2014-06-30 Sold Out -0.48%$97.7 - $125.07
($110.33)
$ 125.9214%Sold Out0
SLXPAndreas Halvorsen 2014-03-31 Buy 0.67%$88.8 - $114.64
($101.95)
$ 125.9224%New holding, 1551766 sh.1,551,766
SLXPJoel Greenblatt 2014-03-31 Buy 0.48%$88.8 - $114.64
($101.95)
$ 125.9224%New holding, 307445 sh.307,445
SLXPJoel Greenblatt 2013-09-30 Sold Out -0.36%$65.73 - $75.54
($68.97)
$ 125.9283%Sold Out0
SLXPJoel Greenblatt 2013-06-30 Buy 0.36%$47.72 - $66.83
($57.19)
$ 125.92120%New holding, 127495 sh.127,495
SLXPVanguard Health Care Fund 2013-03-31 Add0.08%$40.472 - $51.37
($47.96)
$ 125.92163%Add 22.44%2,147,945
SLXPJoel Greenblatt 2013-03-31 Sold Out -0.15%$40.472 - $51.37
($47.96)
$ 125.92163%Sold Out0
SLXPJoel Greenblatt 2012-12-31 Add0.06%$37.97 - $42.9
($40.82)
$ 125.92208%Add 75.81%63,399
SLXPNWQ Managers 2012-12-31 Sold Out -0.17%$37.97 - $42.9
($40.82)
$ 125.92208%Sold Out0
SLXPJoel Greenblatt 2012-09-30 Buy 0.1%$41.92 - $55.65
($47.44)
$ 125.92165%New holding, 36061 sh.36,061
SLXPNWQ Managers 2012-03-31 Reduce-0.14%$45.72 - $53.75
($46.12)
$ 125.92173%Reduce -40.33%656,533
SLXPNWQ Managers 2011-09-30 Add0.18%$26.18 - $40.9
($33.07)
$ 125.92281%Add 198.07%1,320,679
SLXPVanguard Health Care Fund 2011-09-30 Add0.09%$26.18 - $40.9
($33.07)
$ 125.92281%Add 55.43%1,554,300
SLXPJohn Paulson 2011-09-30 Sold Out -0.2056%$26.18 - $40.9
($33.07)
$ 125.92281%Sold Out0
SLXPJohn Paulson 2011-06-30 Add0.19%$34.69 - $40.57
($37.85)
$ 125.92233%Add 971.43%1,500,000
SLXPNWQ Managers 2011-06-30 Buy 0.09%$34.69 - $40.57
($37.85)
$ 125.92233%New holding, 443084 sh.443,084
SLXPGeorge Soros 2011-06-30 Sold Out $34.69 - $40.57
($37.85)
$ 125.92233%Sold Out0
SLXPJohn Paulson 2011-03-31 Buy 0.01%$31.61 - $48.03
($38.86)
$ 125.92224%New holding, 140000 sh.140,000
SLXPGeorge Soros 2011-03-31 Reduce$31.61 - $48.03
($38.86)
$ 125.92224%Reduce -95.44%5,700
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SLXP is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
SLXP Andreas Halvorsen 2014-09-302,719,5384.271.7-5.88%
SLXP Vanguard Health Care Fund 2014-09-301,538,0452.410.61-15.7%
Premium Most recent portfolio changes are included for Premium Members only!


SLXP: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Forbes William PEVP Research&Devel & CDO 2014-11-12Sell11,079$95.0532.48view
CREECH TIMOTHY JSee Remarks 2014-11-05Sell0$032.48view
LOGAN CAROLYN JPresident & CEO 2014-06-26Sell53,057$123.382.06view
Scruggs Rick DExecutive Vice President 2014-05-16Sell900$105.6719.16view
D ALONZO THOMASDirector 2014-04-22Sell11,530$110.8913.55view
Scruggs Rick DExecutive Vice President 2014-03-04Sell1,319$110.6613.79view
CHAPPELL JOHN FDirector 2014-03-04Sell10,000$112.212.23view
D ALONZO THOMASDirector 2014-01-10Sell12,050$91.8337.12view
DERBYSHIRE ADAM CEVP Finance/CFO 2014-01-09Sell30,001$91.4837.65view
Forbes William PEVP Research&Devel & CDO 2014-01-08Sell8,000$90.0639.82view

Press Releases about SLXP :

Quarterly/Annual Reports about SLXP:

News about SLXP:

Articles On GuruFocus.com
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Salix Pharmaceu Dec 12 2014 
Pharmaceutical Giant Merck Buys Cubist Pharma Dec 09 2014 
Bill Ackman and Valeant Could Sweeten Allergan Deal By $15 A Share Oct 10 2014 
Steven Cohen Has a Track Record of Impressive Returns Jul 31 2014 
Joel Greenblatt's Gotham Capital Top 5 New Stocks May 16 2014 
Weekly CFO Sells Highlight: FII, SLXP, CCK, VCI, WDC, STMP Dec 31 2012 
Weekly Guru Bargains Highlights: HMSY, FB, TSU, SLXP, ANR Oct 29 2012 
Value Shop Nuveen Investments Reports Second Quarter Portfolio Aug 19 2011 
Hedge Fund Giant John Paulson Reports Q2 Portfolio Aug 15 2011 
Salix Pharmaceuticals Ltd. (SLXP) President & CEO Carolyn J Logan sells 14,000 Shares Sep 23 2010 

More From Other Websites
Nasdaq stocks posting largest percentage decreases Jan 23 2015
Salix Pharmaceuticals Jan 20 2015
Salix Pharma Reportedly Exploring Sale; Stock Up Jan 20 2015
Salix's HQ building in Raleigh sells for $27 million Jan 16 2015
SALIX PHARMACEUTICALS LTD Files SEC form 8-K, Entry into a Material Definitive Agreement Jan 12 2015
The Shuman Law Firm Investigates Salix Pharmaceuticals Ltd. Jan 09 2015
SALIX PHARMACEUTICALS LTD Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 09 2015
Pharming and Salix Announce First Patient Treated in Clinical Study of Ruconest® for Prophylaxis of... Jan 08 2015
Pharming and Salix Announce First Patient Treated in Clinical Study of Ruconest® for Prophylaxis of... Jan 08 2015
Pharming And Salix Announce First Patient Treated In Clinical Study Of Ruconest® For Prophylaxis Of... Jan 08 2015
Pharming and Salix Announce First Patient Treated in Clinical Study of Ruconest® for Prophylaxis of... Jan 08 2015
Why Salix's CEO Departure Could Signal a Sale Jan 06 2015
Is Salix Pharmaceuticals Hanging a 'For Sale' Sign Outside? Jan 06 2015
Salix Pharmaceuticals CEO Plans to Retire Jan 05 2015
Amid turmoil at Raleigh's biggest pharma, Salix CEO retires Jan 05 2015
Salix CEO to Retire in Latest Departure From Drugmaker Jan 05 2015
Carolyn Logan to Retire as Chief Executive Officer of Salix Pharmaceuticals Jan 05 2015
SALIX PHARMACEUTICALS LTD Files SEC form 8-K, Change in Directors or Principal Officers, Other... Jan 05 2015
Carolyn Logan to Retire as Chief Executive Officer of Salix Pharmaceuticals Jan 05 2015
SLXP Investor Alert: Levi & Korsinsky, LLP Reminds Investors of Class Action against Salix... Jan 02 2015

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK